CORRECTION Open Access

Correction to: The cost-effectiveness of albumin in the treatment of decompensated cirrhosis in Germany, Italy, and Spain



M. Chris Runken¹, Paolo Caraceni², Javier Fernandez^{3,4}, Alexander Zipprich⁵, Rashad Carlton^{6*} and Martin Bunke⁷

Correction to: Health Economics Review (2019) 9:22 https://doi.org/10.1186/s13561-019-0237-7

Following publication of the original article [1], the authors reported that one of the numbers within Fig. 6 contains a mistake.

The correct Fig. 6 is shown below.

Author details

¹Grifols Shared Services North America (SSNA), Inc, Research Triangle Park, Raleigh, NC, USA. ²Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy. ³Liver ICU, Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain. ⁴European Foundation of Chronic Liver Failure (EF-Clif), Barcelona, Spain. ⁵Department of Internal Medicine I, Martin-Luther-University Halle-Wittenberg, Halle, Germany. ⁶Xcenda L.L.C, Palm Harbor, FL, USA. ⁷Senior Director Medical Affairs, Retrophin, San Diego, CA, USA.

Published online: 17 April 2020

Reference

 Runken, et al. The cost-effectiveness of albumin in the treatment of decompensated cirrhosis in Germany, Italy, and Spain. Health Economics Review. 2019;9:22. https://doi.org/10.1186/s13561-019-0237-7.

⁶Xcenda L.L.C, Palm Harbor, FL, USA



^{*} Correspondence: rashad.carlton@xcenda.com
The original article can be found online at https://doi.org/10.1186/s13561-019-0237-7

Runken et al. Health Economics Review (2020) 10:8 Page 2 of 2

